COPENHAGEN, Denmark, July 1, 2026
Evaxion A/S announced that it will present new preclinical data for its investigational cytomegalovirus (CMV) vaccine candidate EVX-V1 at the International Herpesvirus Workshop (IHW) 2026, taking place July 11–15 in Montreal, Canada. The poster presentation will highlight findings generated using the company’s proprietary AI-Immunology™ platform, which are expected to guide the final antigen selection for a broadly protective next-generation CMV vaccine. The new data represent another milestone in the development of EVX-V1, a multi-component vaccine candidate that combines AI-discovered novel antigens with AI-optimized versions of established CMV vaccine antigens. According to the company, the findings support continued advancement of the program as planned while reinforcing the potential of artificial intelligence to accelerate vaccine discovery and development for infectious diseases.
Preclinical Results Strengthen EVX-V1 Development Strategy
The poster, titled “AI-driven multi-antigen vaccine design to address cytomegalovirus infection, latency, and immune evasion,” will present new evidence supporting antigen selection for EVX-V1. The investigational vaccine is designed to target multiple stages of CMV infection, including viral infection, latency, and immune evasion, through a multi-antigen strategy intended to provide broader and more durable immune protection. By combining previously undiscovered CMV antigens identified through artificial intelligence with an AI-optimized pre-fusion glycoprotein B (gB) antigen, Evaxion aims to improve immune responses beyond those achieved with conventional vaccine approaches. The company stated that the latest preclinical findings will help finalize the antigen composition before advancing the vaccine into future stages of development.
AI-Immunology™ Platform Expands Vaccine Innovation
Evaxion’s proprietary AI-Immunology™ platform uses artificial intelligence to identify novel vaccine targets, optimize antigen design, and accelerate the development of vaccines for both infectious diseases and cancer. Through this platform, researchers identified previously unexplored CMV antigens capable of generating specific immune responses while reducing viral infection and limiting cell-to-cell viral spread in preclinical laboratory and animal models. The company’s proprietary AI-optimized pre-fusion glycoprotein B has also demonstrated superior neutralizing activity compared with traditional gB antigens, supporting the potential for improved vaccine efficacy. Together, these technologies form the scientific foundation of EVX-V1, positioning it as a differentiated candidate in the search for an effective CMV vaccine.
Advertisement
Growing Need for an Effective CMV Vaccine
Cytomegalovirus (CMV) remains one of the most significant unmet needs in infectious disease prevention, with no approved vaccine currently available despite decades of research. Approximately 1 in 200 newborns is affected by congenital CMV infection, and nearly 20% of infected infants develop long-term complications, including hearing loss, vision impairment, intellectual disability, and developmental disorders. The virus also poses serious health risks for immunocompromised individuals, including transplant recipients and patients with weakened immune systems. As global demand for improved CMV prevention continues to grow, Evaxion believes its AI-powered vaccine discovery platform and EVX-V1 could provide a promising next-generation approach to addressing this widespread viral infection. The upcoming presentation at the International Herpesvirus Workshop 2026 represents another important milestone in the company’s Bio-Pharma pipeline as it advances innovative vaccine candidates for diseases with substantial unmet medical needs.
Source: Evaxion press release
